Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Vir Biotechnology, Inc..
Vir Biotechnology, Inc. is a company.
Key people at Vir Biotechnology, Inc..
Key people at Vir Biotechnology, Inc..
Vir Biotechnology, Inc. (Nasdaq: VIR) is a clinical-stage immunology company dedicated to developing novel therapeutics that harness the immune system to treat and prevent serious infectious diseases, with a pipeline advancing monoclonal antibodies, siRNA-based treatments, and other platforms targeting viruses like hepatitis B, influenza, HIV, and SARS-CoV-2, as well as expanding into oncology.[1][5][6] Founded to address a gap in biopharma's focus on infectious diseases, Vir combines immunologic insights with technologies like next-generation antibodies and PRO-XTEN® protease-releasable masking to rapidly advance candidates from discovery to clinical trials, serving patients with unmet needs in viral infections and cancer.[1][2][5] The company has demonstrated growth through strategic acquisitions, major funding rounds exceeding $500 million early on, a 2019 IPO raising $143 million, and partnerships like one with GSK, positioning it as a leader in immune-based therapies amid public health challenges like COVID-19.[1][2]
Vir Biotechnology emerged in January 2016 (with public launch announced January 5, 2017) in San Francisco, California, conceived by ARCH Venture Partners' Robert Nelsen to fill a void in infectious disease innovation, as large pharma had deprioritized antivirals, vaccines, and antibacterials for diseases like hepatitis, influenza, and tuberculosis.[1][2][4] Scientific founders included immunology experts Klaus Frueh, Louis Picker (a physician-scientist specializing in immune responses to viruses and ongoing scientific advisor), Jay Parrish, Larry Corey, and Phil Pang, building on technologies from Oregon Health & Science University and predecessor TomegaVax (acquired early via Bill & Melinda Gates Foundation connections).[1][2][3][4] George Scangos, former Biogen CEO, joined as CEO shortly after, leading rapid scaling to over 200 employees by 2020 with four platforms in clinical trials; the company secured $150 million from ARCH, $500 million from SoftBank Vision Fund in 2017 (enabling Humabs BioMed acquisition), and diverse backing from Gates Foundation, sovereign funds, and others.[1][2][4] Pivotal early traction included 2017 SoftBank investment for pipeline expansion and pre-COVID advantages like SARS-recovered patient antibodies.[1][2]
Vir stands out in immunology through integrated platforms and execution speed:
Vir rides the wave of immunology reprogramming and synthetic biology advances (e.g., CRISPR, novel vaccines, AI drug discovery), applying them purposefully to infectious diseases amid pharma's retreat from antivirals—critical timing post-COVID, where its pre-existing SARS antibodies gave a competitive edge in therapies for emerging pathogens.[1][2][4] Market forces like rising drug-resistant bacteria, chronic viruses (hepatitis delta as lead), and oncology unmet needs favor its multi-program approach, influencing the ecosystem by reviving focus on high-burden diseases via acquisitions, massive early funding, and public-private partnerships (Gates Foundation, SoftBank).[1][2][4][5] As a Nasdaq player, Vir boosts biotech's pipeline diversity, collaborating with academia/industry to address global health threats, potentially reshaping standards for immune therapies beyond pandemics.[3][6]
Vir's momentum hinges on clinical readouts for its hepatitis delta program and oncology expansions, with next earnings on February 19, 2026, amid a negative P/E (-1.65) reflecting R&D investment phase but underscoring high-upside potential in immunology.[3] Trends like AI-accelerated discovery, masking tech for precision delivery, and post-pandemic pathogen preparedness will propel it, potentially evolving influence through more GSK-like deals or approvals transforming chronic infection treatment. As an originator of immune-focused biopharma revival, Vir remains poised to deliver on its founding vision of a world without infectious disease.[2][5]
